Bionano genomics news.

News Release Details « Back. Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress. May 05, 2022 | PDF Version - 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and …SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting. “We appreciate …The market expects Bionano Genomics, Inc. (BNGO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022.Complete Bionano Genomics Inc. stock information by Barron's. View real-time BNGO stock price and news, along with industry-best analysis.

News Release Details « Back. Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress. May 05, 2022 | PDF Version - 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and …Mar 7, 2023 · Bionano Genomics. Market Cap. $61M. Today's Change. (4.64%) $0.07. Current Price. $1.58. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ ...

UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the …

News Release Details « Back. Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress. Nov 03, 2022 | PDF Version – 55% year-over-year revenue growth in Q3 2022 – On track to achieve all 2022 ELEVATE! milestones – Strong balance sheet with $180.2 million in cash, cash …Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Bionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago.We would like to show you a description here but the site won’t allow us.Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress. 02 Nov '23. Thompson and Thompson Genetics and Genomics in Medicine Includes OGM …

SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to …

Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million , which wouldAlbino parakeets are those that exhibit a mutation in the color-producing portion of their genome. The gene that causes the mutation is called the ino gene. However, because there are two different basic colorations for parakeets—blue and...See Bionano Genomics, Inc. (BNGO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Bionano said it expected revenue of $7.3 million to $7.5 million in the first quarter, representing an increase of 28% to 32%, year over year. That would also mean the 10th consecutive quarter of ...By Robert Lakin, InvestorPlace Contributor Jun 7, 2021, 9:34 am EST. Investors in Bionano Genomics (NASDAQ: BNGO) Monday morning are picking up where they left off on Friday, boosting the shares ...Bionano Genomics: PB2245: A combination of exome sequencing and optical genome mapping unveils a dual molecular diagnosis in a case with an unknown neurodevelopmental disorder Acharya A. Columbia University: PB2261: B-allele frequency-based approach to detecting absence of heterozygosity using optical genome mapping …

Q4 revenue was $8.2 million, which represents a 30% increase over Q4 2021; 2022 revenue was $27.8 million, which represents a 55% increase over year end 2021; Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021; Conference call today, March 9 th, 2023 at 4:30 PM ET SAN …Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its ...SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theSAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ...

SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …

The average price point forecasted by analysts for Bionano Genomics Inc (BNGO) is $12.33, which is $10.7 above the current market price. The public float for BNGO is 38.09M, and currently, short sellers hold a 17.35% ratio of that float. The average trading volume of BNGO on November 27, 2023 was 888.80K shares. Top 5 EV Tech Stocks to …SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that it has entered into a definitive agreement to acquire Purigen Biosystems, Inc. (Purigen), a company that develops and commercializes automated nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP ...Bionano Genomics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies. News Coverage …NEW YORK (GenomeWeb) – Bionano Genomics has priced its initial public offering of 3.36 million units at $6.125 per unit, bringing in total gross proceeds of $20.58 million, and has started trading on the Nasdaq. Each unit consists of one share of common stock and a five-year warrant to purchase another share of common stock at $6.125.Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 [email protected] 7, 2023 · Bionano Genomics (NASDAQ: BNGO) effected a 1-for-10 reverse stock split and announced that it will publish quarterly earnings on Aug. 9. Shares opened this morning at $4.73 each, a market ... News Release Details « Back. Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results. Jan 05, 2023 | PDF Version - Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 - Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021 ...11 Jul 2023 ... BNGO stock is receiving lots of attention from retail investors, some who claim Bionano Genomics stock ... BREAKING NEWS - Bionano CFO Reveals Why ...BNGO: Get the latest Bionano Genomics stock price and detailed information including BNGO news, historical charts and realtime prices. Indices Commodities Currencies StocksThe word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNano Genomics with a $2.67 average price target, which is a 281.43% upside from current levels.

9 Mei 2023 ... News Release Details. « Back. Bionano Reports First Quarter 2023 ... Bionano Genomics is a provider of genome analysis solutions that can ...

The market expects Bionano Genomics, Inc. (BNGO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022.

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT).Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire.News Release Details « Back. Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies. Feb 22, 2023 | PDF Version. ... About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers …During the first quarter of 2021, BioNano's sales grew by 179% year over year to $3.2 million. Keep in mind, however, that many of its potential customers temporarily shut down their lab ...News Release Details « Back. Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress. Aug 04, 2022 | PDF Version - 73% year-over-year revenue growth in Q2 2022 - Achieved all 1H 2022 ELEVATE! milestones - Strong balance sheet with $187.3 million in cash, cash equivalents, and …Mar 9, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theSAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. The Company’s common stock …

SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that it has entered into a definitive agreement to acquire Purigen Biosystems, Inc. (Purigen), a company that develops and commercializes automated nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP ...In the Medical Instruments & Supplies industry, which ranks 77 out of 146 industries, BioNano Genomics Inc ranks higher than 0% of stocks. BioNano Genomics …Company profile page for Bionano Genomics Inc including stock price, company news, press releases, executives, board members, and contact informationInstagram:https://instagram. best precious metal etfamerican assets trust incram stockwhat is the best financial magazine Pharma, BioPharma. Bionano frames $90M BioDiscovery buy as way to expand genomics analysis Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal.Bionano Genomics SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company … best health insurance plans for independent contractorsbest currencies to trade For the last reported quarter, it was expected that Bionano Genomics, Inc. Would post a loss of $0.90 per share when it actually produced a loss of $1.24, delivering a surprise of -37.78%. buy nintendo stock 13 Jun 2023 ... News Release Details. « Back. Bionano Announces Presentation of OGM ... © 2023 Bionano Genomics, Inc. All rights reserved. For Research Use ...Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome. Enter a new era of optical genome …Visualize multiple tracks of genomic data for the at-a-glance context of variant calls. NₓClinical offers multi-platform integration by: Combining current and historical molecular data from array and sequencing for sample continuity. Comparing and contrasting outputs from multiple technologies to understand the underlying biology.